Only in Titles

Search results for: antibody

paperclip

#34706311   2021/10/16 To Up

Denosumab did not improve computerized tomography erosion scores when added to intensive urate-lowering therapy in gout: Results from a pilot randomized controlled trial.

Disordered osteoclast activity has been implicated in the pathogenesis of gouty bone erosion. We sought to determine if the addition of denosumab (a monoclonal antibody targeting the receptor activator of nuclear factor kappa-B ligand - RANKL) to intensive urate-lowering therapy (ULT) improves gouty bone erosion.
Angelo L Gaffo, Kenneth Saag, Anthony J Doyle, Joshua Melnick, Anne Horne, Jeffrey Foster, Amy Mudano, Stephanie Biggers-Clark, David Redden, Nicola Dalbeth

1741 related Products with: Denosumab did not improve computerized tomography erosion scores when added to intensive urate-lowering therapy in gout: Results from a pilot randomized controlled trial.

100 100 μg100 100 μg1 mg

Related Pathways

paperclip

Error loading info... Pleas try again later.
paperclip

#34706271   2021/10/16 To Up

Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain.

Antibodies that potently neutralize SARS-CoV-2 target mainly the receptor-binding domain or the N-terminal domain (NTD). Over a dozen potently neutralizing NTD-directed antibodies have been studied structurally, and all target a single antigenic supersite in NTD (site 1). Here, we report the cryo-EM structure of a potent NTD-directed neutralizing antibody 5-7, which recognizes a site distinct from other potently neutralizing antibodies, inserting a binding loop into an exposed hydrophobic pocket between the two sheets of the NTD β sandwich. Interestingly, this pocket was previously identified as the binding site for hydrophobic molecules, including heme metabolites, but we observe that their presence does not substantially impede 5-7 recognition. Mirroring its distinctive binding, antibody 5-7 retains neutralization potency with many variants of concern (VOCs). Overall, we reveal that a hydrophobic pocket in NTD proposed for immune evasion can be used by the immune system for recognition.
Gabriele Cerutti, Yicheng Guo, Pengfei Wang, Manoj S Nair, Maple Wang, Yaoxing Huang, Jian Yu, Lihong Liu, Phinikoula S Katsamba, Fabiana Bahna, Eswar R Reddem, Peter D Kwong, David D Ho, Zizhang Sheng, Lawrence Shapiro

1251 related Products with: Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain.

100 ug100ug100ug Lyophilized100μg200ul250ul100 ug100ug Lyophilized250ul100ug Lyophilized100 ug200ul

Related Pathways

paperclip

#34706189   2021/10/27 To Up

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.

Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease.
Anil Gupta, Yaneicy Gonzalez-Rojas, Erick Juarez, Manuel Crespo Casal, Jaynier Moya, Diego R Falci, Elias Sarkis, Joel Solis, Hanzhe Zheng, Nicola Scott, Andrea L Cathcart, Christy M Hebner, Jennifer Sager, Erik Mogalian, Craig Tipple, Amanda Peppercorn, Elizabeth Alexander, Phillip S Pang, Almena Free, Cynthia Brinson, Melissa Aldinger, Adrienne E Shapiro,

2746 related Products with: Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.

100ug Lyophilized200ul1 mg200ul200ul100ug Lyophilized200ug200ul200ul200ul100 200ul

Related Pathways

paperclip

#34706178   // To Up

Audio Interview: A New Monoclonal Antibody for Covid-19 and Potential Vaccination for Children.


Eric J Rubin, Lindsey R Baden, Stephen Morrissey

1787 related Products with: Audio Interview: A New Monoclonal Antibody for Covid-19 and Potential Vaccination for Children.

0.2 mg25 µg25 µg0.25 mg100 TESTS0.2 mg1 ml 1 G 100ul 100ul100μg 100ul

Related Pathways

    No related Items
paperclip

#34706172   // To Up

Risankizumab in Severe Asthma - A Phase 2a, Placebo-Controlled Trial.

Interleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23 in the treatment of asthma improves disease control and reduces airway inflammation is unclear.
Christopher E Brightling, Parameswaran Nair, David J Cousins, Renaud Louis, Dave Singh

2325 related Products with: Risankizumab in Severe Asthma - A Phase 2a, Placebo-Controlled Trial.

5 100 μg1 mg100 μg100 μg100 μg3 mg100 μg100 μg

Related Pathways

paperclip

#34706171   // To Up

Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma.

Monoclonal antibodies targeting IgE, interleukin-4 and -13, and interleukin-5 are effective in treating severe type 2 asthma, but new targets are needed. Itepekimab is a new monoclonal antibody against the upstream alarmin interleukin-33. The efficacy and safety of itepekimab as monotherapy, as well as in combination with dupilumab, in patients with asthma are unclear.
Michael E Wechsler, Marcella K Ruddy, Ian D Pavord, Elliot Israel, Klaus F Rabe, Linda B Ford, Jorge F Maspero, Raolat M Abdulai, Chih-Chi Hu, Renata Martincova, Andreas Jessel, Michael C Nivens, Nikhil Amin, David M Weinreich, George D Yancopoulos, Helene Goulaouic

1759 related Products with: Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma.

1 Set100ul1 mg1 Set100 ug2 105

Related Pathways

paperclip

#34706153   2021/10/27 To Up

First evidence of human-to-dog transmission of SARS-CoV-2 B.1.160 variant in France.

Since the start of the COVID-19 pandemic, several episodes of human-to-animal SARS-CoV-2 transmission have been described in different countries. The role of pets, especially domestic dogs, in the COVID-19 epidemiology is highly questionable and needs further investigation. In this study, we report a case of COVID-19 in a French dog living in close contact with its owners who were COVID-19 patients. The dog presented rhinitis and was sampled one week after its owners (a man and a woman) were tested positive for COVID-19. The nasal swabs for the dog tested remained positive for SARS-CoV-2 by RT-qPCR one month following the first diagnosis. Specific anti- SARS-CoV-2 antibodies were detectable 12 days after the first diagnosis and persisted for at least five months as tested using ELISA and automated western blotting. The whole-genome sequences from the dog and its owners were 99%-100% identical (with the man and the woman's sequences, respectively) and matched the B.1.160 Variant of concern (Marseille-4 variant), the most widespread in France at the time the dog was infected. This study documents the first detection of B.1.160 in pets (a dog) in France, and the first canine genome recovery of the B.1.160 variant of global concern. Moreover, given the enhanced infectivity and transmissibility of the Marseille-4 variant for humans, this case also highlights the risk that pets may potentially play a significant role in SARS-CoV-2 outbreaks and may transmit the infection to humans. We have evidence of human-to-dog transmission of the Marseille-4 variant, since the owners were first to be infected. Finally, owners and veterinarians must be vigilent for canine COVID-19 when dogs are presented with respiratory clinical signs. This article is protected by copyright. All rights reserved.
Hacène Medkour, Sébastien Catheland, Corine Boucraut-Baralon, Younes Laidoudi, Youssouf Sereme, Jean-Luc Pingret, Matthieu Million, Linda Houhamdi, Anthony Levasseur, Julien Cabassu, Bernard Davoust

2808 related Products with: First evidence of human-to-dog transmission of SARS-CoV-2 B.1.160 variant in France.

100ug Lyophilized20ug100ug Lyophilized100ug Lyophilized25mg100ug Lyophilized20ug1016 Arrays/Slide100 μg2

Related Pathways

paperclip

Error loading info... Pleas try again later.
paperclip

#34706134   2021/10/27 To Up

Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker.

COVID-19 pandemic caused by SARS-CoV-2 has become a public health crisis worldwide. In this study we aimed at demonstrating the neutralizing potential of the IgY produced after immunizing chicken with a recombinant SARS-CoV-2 spike protein S1 subunit.
Lirong Bao, Cheng Zhang, Jinglu Lyu, Ping Yi, Xin Shen, Boyu Tang, Hang Zhao, Biao Ren, Yu Kuang, Linlin Zhou, Yan Li

2268 related Products with: Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker.

100 100200ul100 100 G500200ug1 kit25ml200ul1000

Related Pathways